Kymab is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a fu...
Kymab is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available. Kymab's platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently. Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. Kymab was founded in 2010 and has raised over US$220m of equity financing. It has an experienced management team with a successful track record in drug discovery and development and a broad pipeline of therapeutic antibody programmes in immune-oncology, auto-immunity, haematology, infectious disease and other areas.
Founded Year
2010
Organization Website
kymab.com
Organization Languages
English
Organization Revenue
7000
Current Technologies
123-reg dns
mimecast
digitalocean
ubuntu
django
google analytics
typekit
nginx
mobile friendly
Job Functions
Consulting
Information Technology
Business Development
Support
Engineering
Human Resources
Operations
Entrepreneurship
fully human monoclonal antibodies
drug discovery
drug development
advanced human antibody drug discovery & development